3rd Annual Pharma Pricing Strategies - Jacob Fleming Group

15th-16th January 2008, Hotel Radisson SAS, Rome, Italy
This event will bring together the Pharma Industry experts to benchmark the best practices in health economics, and their experience with benefit evaluations and reference pricing approach. During two days, the participants will have the opportunity to compare and contrast different pricing and reimbursement policies across the European markets.

Setting the right price and ensuring that the product is adequately reimbursed is vital for a company's profitability. Leading pharmaceutical companies understand, how to succeed in a regulatory uncertainty, cost - containment efforts and governmental pressure to lower the drugs' prices. Overcoming pricing & reimbursement hurdles is crucial for achieving a rapid market access.

Key Speakers:

  • Mondher Toumi, Vice President Pricing, Reimbursement & Health Outcomes, Lundbeck, France
  • Sylvie Gabriel, Vice President Global Health Outcomes and Market Access, Sanofi Aventis, France
  • Peter Sawicki, Institute's Director, IQWIG, Germany
  • Koen Torfs, Vice President Health Economics and Pricing, Janssen Cilag, Germany
  • Altan Demirdere, Managing Director, Novartis, Turkey
  • Fernando Royo, Vice President & General Manager, Genzyme, Spain

Key topics:

  • Benchmarking different pricing & reimbursement systems across the European markets
  • Achieving competitive advantage in current pricing & reimbursement environment
  • Keeping the optimal price throughout a drug's life
  • The role of health economics for pricing
  • Best practices in improving market access speed

Who should attend:
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Pricing, Market Pricing, Commercial Pricing, Pricing Strategists, Pricing & Reimbursement, Health Economics, Outcomes Research, Regulatory Affairs, Governmental Affairs, Public Affairs, Public Policy Directors, Operations, Government bodies, Regulatory Bodies

For further information and registration, visit the 3rd Annual Pharma Pricing Strategies event pages.

About Jacob Fleming Group
Jacob Fleming Group is one of the world's leading business intelligence companies producing business-to-business conferences which consists of current research, market trends, technological developments and applications. Our market-led intelligence allows our customers to make informed decisions for maximum bottom-line impact.

Jacob Fleming offices in Bratislava (Slovakia), Prague (Czech republic), Budapest (Hungary), Barcelona (Spain), Dubai (UAE) and Cleveland (USA) specialize in organizing prestigious international conferences for Europe and GCC region, providing groundbreaking strategies and proven technical expertise in both business functional areas and vertical markets through energy, finance, media, pharmaceutical and telecom sectors. For more information, visit www.jacobfleming.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...